Literature DB >> 11509861

Insulin resistance in nonobese patients with polycystic ovary syndrome.

S Toprak1, A Yönem, B Cakir, S Güler, O Azal , M Ozata, A Corakçi.   

Abstract

OBJECTIVES: Most patients with polycystic ovary syndrome (PCOS) are obese and known to have insulin resistance. Obesity per se is a cause of insulin resistance. This study was performed to determine whether insulin resistance occurs in patients with PCOS in the absence of obesity and acanthosis nigricans.
METHOD: For this purpose, an euglycemic hyperinsulinemic clamp study was performed in 12 nonobese patients with PCOS and in 10 healthy control subjects matched for age and weight.
RESULTS: The mean serum testosterone and luteinizing hormone (LH) levels were significantly elevated (4.09 +/- 1.32 vs. 1.18 +/- 0.53 pg/ml, p < 0.001, and 11.63 +/- 5.37 vs. 4.98 +/- 2.73 mIU/ml, p < 0.001, respectively), and the serum sex hormone binding globulin level was significantly reduced (40.96 +/- 14.94 vs. 73.98 +/- 30.40 nmol/l, p < 0.001) in patients with PCOS as compared with the values in control subjects. The mean serum insulin level was also elevated in patients with PCOS as compared with control subjects (32.33 +/- 4.98 vs. 19.56 +/- 2.21 microU/ml, p < 0.05). The insulin sensitivity was lower in patients with PCOS as compared with the control subjects (200 +/- 27.8 vs. 427.8 +/- 88.9 micromol x kg(-1) x min(-1), p < 0.001). In patients with PCOS, the serum levels of free testosterone (r = -0.89, p < 0.001) and LH were inversely correlated with the insulin sensitivity (r = -0.63, p < 0.05). Serum follicle-stimulating hormone, prolactin, and dehydroepiandrosterone sulfate levels were similar in both groups.
CONCLUSIONS: These results indicate that a significant degree of insulin resistance exists in nonobese patients with PCOS and that this insulin resistance is significantly related to serum LH and free testosterone levels. Thus, measures to decrease insulin resistance may have to be considered earlier to decrease the potential risks of developing diabetes mellitus and coronary artery disease at later ages of life in these patients. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509861     DOI: 10.1159/000049972

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  29 in total

1.  Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome.

Authors:  Claudia Gagnon; Jean-Patrice Baillargeon
Journal:  CMAJ       Date:  2007-03-27       Impact factor: 8.262

Review 2.  Neuroendocrine dysfunction in PCOS: a critique of recent reviews.

Authors:  Suhail A R Doi
Journal:  Clin Med Res       Date:  2008-09

3.  Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome.

Authors:  S A R Doi; M Al-Zaid; P A Towers; C J Scott; K A S Al-Shoumer
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

4.  Morning blood pressure surge and its relation to insulin resistance in patients of reproductive age with polycystic ovary syndrome.

Authors:  Hasan Kadi; Eyup Avci; Akin Usta; Abdullah Orhan Demirtaş
Journal:  Reprod Biol Endocrinol       Date:  2018-08-09       Impact factor: 5.211

5.  Age at menarche and risk of type 2 diabetes: results from 2 large prospective cohort studies.

Authors:  Chunyan He; Cuilin Zhang; David J Hunter; Susan E Hankinson; Germaine M Buck Louis; Mary L Hediger; Frank B Hu
Journal:  Am J Epidemiol       Date:  2009-12-21       Impact factor: 4.897

Review 6.  Polycystic ovary syndrome.

Authors:  Zi-Jiang Chen; Yuhua Shi
Journal:  Front Med China       Date:  2010-08-12

Review 7.  Female infertility: which role for obesity?

Authors:  Alessandra Gambineri; Daniela Laudisio; Chiara Marocco; Stefano Radellini; Annamaria Colao; Silvia Savastano
Journal:  Int J Obes Suppl       Date:  2019-04-12

8.  Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome?

Authors:  M Bahceci; A Tuzcu; S Bahceci; S Tuzcu
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

Review 9.  Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Juan Pablo Domecq; Gabriela Prutsky; Rebecca J Mullan; Vishnu Sundaresh; Amy T Wang; Patricia J Erwin; Corrine Welt; David Ehrmann; Victor M Montori; Mohammad Hassan Murad
Journal:  J Clin Endocrinol Metab       Date:  2013-10-03       Impact factor: 5.958

10.  Metabolic abnormalities in adolescents with polycystic ovary syndrome in south China.

Authors:  Jia Huang; Renmin Ni; Xiaoli Chen; Lili Huang; Yaqin Mo; Dongzi Yang
Journal:  Reprod Biol Endocrinol       Date:  2010-11-17       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.